Wang et al. [44] reported that combining TKIs and thoracic SBRT resulted in better PFS than that of TKIs alone in patients with EGFR-mutated multimetastatic NSCLC, with acceptable toxicity in clinical practice. Here, EGFR is linked to non-small cell lung carcinoma.